Key facts
- It has raised $650K; the latest was Seed Round ($280K) in Apr 2025.
- Notable investors include Innovatiefonds Noord-Holland, Libertatis Ergo Holding (LEH), PLNT., ROM InWest, SmiLe Incubator — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Amplio Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Amplio Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amplio Pharma
Developer of improved versions of existing drugs intended to make successfu treatment for rheumatoid arthritis patients. The company uses its proprietary modified retention technology to amplify the clinical effect of low-dose Methotrexate, the treatment being used in rheumatoid arthritis, enabling healthcare professionals to improve patient response rates.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2020
- Employees
- 4
- Website
- amplio-pharma.com/
- Ownership
- Privately Held (backing)
Amplio Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amplio Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amplio Pharma in its N-PORT filings yet. We sweep new filings monthly.